GlassScriptPhysician profile
Stephen Charles Collins
NPI 1740571652
$483.51
in general payments reported to CMS, 2019-2025
9 companies · $119 in 2025
The $119 reported for 2025 was less than what a typical Reproductive Endocrinology provider received nationally (typical 2025 total: $140).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $148 · 2020: $67.24 · 2021: $27.78 · 2022: $121 · 2025: $119.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $119.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $118.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $214.70 | 2022-2025 | |
| Vertical Pharmaceuticals, LLC | $70.44 | 2019 | |
| Coopersurgical, INC. | $53.20 | 2021-2022 | |
| Abbvie INC. | $42.93 | 2019-2020 | |
| Ferring Pharmaceuticals INC. | $32.41 | 2019 | |
| Therapeuticsmd, INC. | $23.37 | 2020 | |
| Merck Sharp & Dohme LLC | $19.28 | 2019 | |
| Evofem Biosciences, INC. | $14.29 | 2020 | |
| Medicem INC. | $12.89 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Collins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.